Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
Journal of Clinical Oncology, 08/18/09
Van Erp NP et al. - In a trial to identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of toxicities, it was determined that polymorphisms in specific genes encoding for metabolizing enzymes, efflux transporters, and drug targets are associated with sunitinib-related toxicities. A better understanding of genetic and nongenetic determinants of sunitinib toxicity should help to optimize drug treatment in individual pts.
Methods- A multicenter pharmacogenetic association study was performed in 219 pnts treated with single-agent sunitinib.
- 31 single nucleotide polymorphisms in 12 candidate genes, together with several nongenetic variants, were analyzed for a possible association with toxicity.
- Senetic haplotypes were developed and related to toxicity.
- Risk for leukopenia was increased when the G allele in CYP1A1 2455A/G or the T allele in FLT3 738T/C were present or CAG in the NR1I3 (5719C/T, 7738A/C, 7837T/G) haplotype was absent.
- Any toxicity higher than grade 2 prevalence was increased when the T allele of vascular endothelial growth factor receptor 2 1191C/T or a copy of TT in the ABCG2 (-15622C/T, 1143C/T) haplotype were present.
- Risk for mucosal inflammation was increased in the presence of the G allele in CYP1A1 2455A/G and prevalence of hand-foot syndrome was increased when a copy of TTT in the ABCB1 (3435C/T, 1236C/T, 2677G/T) haplotype was present.
Related Articles
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS Trial
Journal of Clinical Oncology, 10/30/09
Relevance Score: 47%
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer
Cancer, 11/18/09
Relevance Score: 44%
The Successful Use of Intralipid for Treatment of Local Anesthetic-induced Central Nervous System Toxicity: Some Considerations for Administration of Intralipid in an Emergency
The Clinical Journal of Pain, 10/21/09
Relevance Score: 44%
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients
Cancer Chemotherapy and Pharmacology, 10/07/09
Relevance Score: 44%
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma
Cancer Chemotherapy and Pharmacology, 11/18/09
Relevance Score: 43%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Complications and side-effects of foam sclerotherapy
Phlebology, 12/09/09
Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review
Headache: The Journal of Head and Face Pain, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor